The objective of this study is to quantify the value of a child born in 27 EU countries and Switzerland. The Human Capital (HC) approach was used to estimate the social benefit arising from an additional childbirth. The value of a newborn child was calculated by summing up the discounted value of all expected future gross earnings of the individual, including an imputed value for household production. The estimation takes into account life expectancy and the probability of being employed or in household production by age-groups. Input data was obtained from Eurostat and the Human Mortality Database. In 2012, the purchasing power parity adjusted present value (PV) of a newborn child was EUR 108.4 thousand in Bulgaria and EUR 803.6 thousand in Denmark. By applying the actual exchange rates, the difference between the lowest value (EUR 48.8 thousand in Bulgaria) and the highest value (EUR 1.1 million in Switzerland) was increased. The PV was highly sensitive to the discount rate. The fertility interventions are expected to gain popularities among other health priorities as a tool to counter generation ageing. However, in order to enhance fertility among other health priorities, policy-makers must take into account the full social value based on the local estimates.
Agency for Health Technology Assessment, Poland (2009): Guidelines for Conducting Health Technology Assessment. http://www.ispor.org/peguidelines/source/Poland_Guidelines-for-Conducting -HTA_English-Version.pdf
Balbo, N. – Billari, F. C. – Mills, M. (2013): Fertility in Advanced Societies: A Review of Research. European Journal of Population, 29(1): 1–38.
Behmane, D. – Lambot, K. – Irs, A. – Steikunas, N. (2002): Baltic Guideline for Economic Evaluation of Pharmaceuticals (Pharmacoeconomic Analysis). Latvian Medicines Pricing and Reimbursement Agency. http://www.zca.gov.lv/english/guidelines.html
Belgian Health Care Knowledge Centre. (2012): Belgian Guidelines for Economic Evaluations and Budget Impact Analyses: Second Edition. https://kce.fgov.be/sites/default/files/page_documents / KCE_183C_economic_evaluations_second_edition_0.pdf
Capri, S. – Ceci, A. – Terranova, L. – Morle, F. – Mantovani, L. (2001): Guidelines for Economic Evaluations in Italy: Recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Information Journal, 35(1): 189–201.
Carone, G. – Denis, C. – Mc Morrow, K. – Mourre, G. – Röger, W. (2006): Long-Term Labour Productivity and GDP Projections for the EU25 Member States: A Production Function Framework. European Economy - Economic Papers (European Commission DG ECFIN), 253: 1–92.
Deonandan, R. – Campbell, M. K. – Østbye, T. – Tummon, I. (2000): Toward a more Meaningful in Vitro Fertilization Success Rate. Journal of Assisted Reproduction and Genetics, 17(9): 498–503.
Dolan, T. J. – Hodgson, T. A. – Wun, W. M. (1980): Present Values of Expected Lifetime Earnings and Housekeeping Services, 1977. Hyattsville: National Center for Health Statistics, Division of Analysis.
Eurostat (2010): Structure of Earnings Survey (ESES) 2010. http://appsso.eurostat.ec.europa.eu/ nui/show.do?dataset=earn_ses_annual&lang=en
Eurostat (2012a): Fertility Statistics. http://epp.eurostat.ec.europa.eu/statistics_explained/index. php/Fertility_statistics Eurostat (2012b): European Union Labor Force Survey (EU-LFS) 2012.
Eurostat (2012c): Mortality Statistics. http://appsso.eurostat.ec.europa.eu/nui/show. do?dataset=demo_mlifetable&lang=en
Eurostat (2012d): Employment Rate by Sex. http://ec.europa.eu/eurostat/tgm/table.do?tab=table&in it=1&language=en&pcode=tsdec420&plugin=1 Eurostat (2012e): Purchasing Power Parities, Price Level Indices and Real Expenditures for ESA95 Aggregates. http://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.do
Gravelle, H. – Smith, D. (2001): Discounting for Health Effects in Cost-Benefit and Cost-Effectiveness Analysis. Health Econ, 10(7): 587–599.
Haikonen, K. – Lillsunde, P. M. – Lunetta, P. – Kokki, E. (2016): Economic Burden of Fire-Related Deaths in Finland, 2000-2010: Indirect Costs Using a Human Capital Approach. Burns, 42(1): 56–62.
Haute Autorité de Santé (2004):Choices in Methods for Economic Evaluation. https://www.hassante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_ evaluation.pdf
Health Information and Quality Authority, Ireland (2014): Guidelines for the Economic Evaluation of Health Technologies in Ireland. https://www.hiqa.ie/sites/default/files/2017-01/Revised_Economic_ Guidelines_posted_100714.pdf
Human Mortality Database (2012): http://www.mortality.org
INFARMED (1998): Guidelines for Economic Drug Evaluation Studies. http://www.ispor.org/ peguidelines/source/PE%20guidelines%20in%20English_Portugal.pdf
Institute for Pharmaeconomic Research (IPF) (2006): Austrian Guidelines on Health Economic Evaluation, Consensus Paper. http://www.ispor.org/peguidelines/source/Guidelines_Austria. pdf
Institute for Quality and Efficiency in Health Care, Germany (2017): General Methods Version 5.0. https://www.iqwig.de/download/Allgemeine-Methoden_Version-5-0.pdf
Laakkeiden Hintalautakunta, Finland (2015): Preparing a Health Economic Evaluation to Be Attached to the Application for Reimbursement Status and Wholesale Price for a Medicinal Product. http://www.hila.fi/c/document_library/get_file?folderId=793451&name=DLFE-9132.pdf
Landefeld, J. S. – Seskin, E. P. (1982): The Economic Value of Life: Linking Theory to Practice. American Journal of Public Health, 72(6): 555–566.
Lopez-Bastida, J. – Oliva, J. – Antonanzas, F. – Garica-Altes, A. – Gisbert, R. – Mar, J. – Puig-Junov, J. (2010): Spanish Recommendations on Economic Evaluation of Health Technologies. European Journal of Health Economics, 11(5): 513–520.
Malinowski, K. P. – Kawalec, P. P. – Moćko, P. (2015): Indirect Costs of Absenteeism due to Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Insulin-Dependent Diabetes Mellitus, and Ulcerative Colitis in 2012: A Study Based on Real-Life Data from the Social Insurance Institution in Poland. Expert Review of Pharmacoeconomics & Outcomes Research, 16(2): 295–303.
Max, W. – Rice, D. P. – Sung, H. Y. – Martha, M. (2002): Valuing Human Life: Estimating the Present Value of Lifetime Earnings. San Francisco: Institute for Health & Aging.
Ministry of Health, Slovak Republic (2011): Guidelines for Economic Evaluation of Health Care Interventions. http://www.zakonypreludi.sk/zz/2011-422
Ministry of Human Resources, Hungary (2017): Az Emberi Erőforrások Minisztériuma szakmai irányelve az egészségügyi technológia értékelés módszertanáról és ennek keretében költséghatékonysági elemzések készítéséről (Professional healthcare guideline on the methodology of health technology assessment). Egészségügyi Közlöny, LXVI(3): 821–842.
NICE (2013): Guide to the Methods of Technology Appraisal 2013. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf
Norwegian Medicines Agency (2012): Guidelines on How to Conduct Pharmacoeconomic Analyses. http://www.ispor.org/peguidelines/source/Norwegian_guidelines2012.pdf
OECD (2013): Statistics on Average Effective Age and Official Age of Retirement in OECD Countries. http://www.oecd.org/els/public-pensions/ageingandemploymentpolicies-statisticson averageeffectiveageofretirement.htm
OECD (2014): OECD Factbook 2013: Economic, Environmental and Social Statistics. OECD Publishing. http://www.oecd-ilibrary.org/sites/factbook-2013-en/01/01/02/index.html?itemId=/ content/chapter/fact book-2013-2-en
Pharmaceutical Benefits Board, Sweden (2003): General Guidelines for Economic Evaluations. http://www.ispor.org/peguidelines/source/Guidelines_in_Sweden.pdf
Savova, A. – Stoimenova, A. – Manova, M. – Zidarova, B. – Petrova, G. – Danchev, N. (2015): Pharmacoeconomic Guideline for Positive Drug List Application Purposes Implemented in Bulgaria. Value Health, 18(7): A548.
Skoupa, J. – Annemans, L. – Hajek, P. (2014): Health Economic Data Requirements and Availability in the European Union: Results of a Survey among 10 European Countries. Value Health Regional Issues, 4: 53–57.
Wallach, E. E. – Vlahos, N. F. (2004): Uterine Myomas: An Overview of Development, Clinical Features, and Management. Obstet Gynecol, 104(2): 393–406.
WHO (2004): Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf
Yli-Kuha, A. N. (2012): Prevalence and Socio-Demographic Determinants of Infertility, Success of Infertility Treatments and Health of Treated Women. Tampere: University of Tampere.
Zorginstituut Nederland, The Netherlands (2016): Guideline for Economic Evaluations in Healthcare. https://www.ispor.org/PEguidelines/source/Netherlands_Guideline_for_economic_evaluations_ in_healthcare.pdf